Thursday, August 16, 2012
Researchers at Stanford University have found that systemic treatment with b-amyloid
peptides can reduce inflammation and reverse paralysis in mouse models of
multiple sclerosis.1 Cardinal Therapeutics Inc. has licensed the work and now is developing
anti-inflammatory amyloids. The company hopes to select a specific indication
and name a lead compound by year end.
Unifying structural features
Cardinal has a program to develop
therapeutic amyloidogenic compounds, and Rothbard said the new findings could
provide additional insights into the structural features underlying the
anti-inflammatory effects of such molecules.
Lou, K.-J. SciBX 5(32);
Published online Aug. 16, 2012
1. Grant, J.L. et al. Sci. Transl.
Med.; published online Aug. 1, 2012;
Contact: Lawrence Steinman, Stanford University,
2. Trapp, B.D. et al. N. Engl. J.
Med. 338, 278-285 (1998)
3. Ferguson, B. et al. Brain 120, 393-399 (1997)
4. Ousman, S.S. et al. Nature 448, 474-479 (2007)
5. Rothbard, J.B. et al. J. Biol.
Chem. 287, 9708-9721 (2012)
AND INSTITUTIONS MENTIONED
Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass.
Cardinal Therapeutics Inc., Menlo Park, Calif.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
(Euronext:SAN; NYSE:SNY), Paris, France
Stanford University, Palo Alto, Calif.
Stanford University School of Medicine, Palo Alto, Calif.